Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer

Aim. The purpose of the present study was to analyze the predictive and prognostic role of soluble (pro)renin receptor (sPRR) as a biomarker for clinicopathological outcome in patients with primary epithelial ovarian cancer (EOC). As part of the renin-angiotensin system (RAS) whose activity is known to increase in ovarian cancer patients, the relation of sPRR and ovarian cancer should be further investigated. Patients and Methods. In this study 197 patients with primary EOC in our institution from 2000 to 2011 were included. sPRR was determined by enzyme-linked immunosorbent assay (ELISA) in preoperative taken blood sera. Associations with clinicopathological outcome were analyzed and serum levels of sPRR in patients have been compared to those in healthy specimen. Kaplan-Meier and logistic/Cox regression assessed the impact of the markers on progression-free survival (PFS) and overall survival (OS). Results. There have been no correlations proved of sPRR levels with neither clinicopathological factors nor prognostic data. Also the distribution of sPRR in patients and controls was normal. Conclusion. sPRR seems to have no predictive, prognostic, or diagnostic value in EOC. As several factors of the RAS which might indicate cancer events have been shown, sPRR seems not to be affected.

[1]  M. Mitchell,et al.  Decidualisation of human endometrial stromal cells is associated with increased expression and secretion of prorenin , 2015, Reproductive Biology and Endocrinology.

[2]  T. Gungor,et al.  Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer , 2015, Archives of Gynecology and Obstetrics.

[3]  L. Huson,et al.  Risk of Ovarian Cancer Relapse Score , 2014, International Journal of Gynecologic Cancer.

[4]  Huirong Shi,et al.  Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer , 2014, Molecular medicine reports.

[5]  T. Hirose,et al.  Plasma Soluble (Pro)Renin Receptor Is Independent of Plasma Renin, Prorenin, and Aldosterone Concentrations But Is Affected by Ethnicity , 2014, Hypertension.

[6]  Daniel Herr,et al.  Local Renin-Angiotensin System in the Reproductive System , 2013, Front. Endocrinol..

[7]  P. Stawowy,et al.  The (pro)renin receptor ((P)RR) can act as a repressor of Wnt signalling. , 2012, Biochemical pharmacology.

[8]  A. Burges,et al.  Ovarian cancer: diagnosis and treatment. , 2011, Deutsches Arzteblatt international.

[9]  Constanze Zeller,et al.  Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival , 2011, Clinical Cancer Research.

[10]  P. Neuhaus,et al.  Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients , 2010, Journal of surgical oncology.

[11]  W. Lichtenegger,et al.  Primary Versus Interval Debulking Surgery in Advanced Ovarian Cancer: Results From a Systematic Single-Center Analysis , 2010, International Journal of Gynecologic Cancer.

[12]  T. Unger,et al.  Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage , 2010, Hypertension Research.

[13]  H. Siragy,et al.  Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression. , 2009, Endocrinology.

[14]  A. Silver,et al.  The opposing roles of Wnt-5a in cancer , 2009, British Journal of Cancer.

[15]  Jaclyn H Neo,et al.  The renin-angiotensin system and malignancy. , 2008, Carcinogenesis.

[16]  W. Border,et al.  Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. , 2008, American journal of physiology. Endocrinology and metabolism.

[17]  Hans Clevers,et al.  Mining the Wnt pathway for cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[18]  H. Kajiyama,et al.  Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival , 2006, British Journal of Cancer.

[19]  C. Nahmias,et al.  Angiotensin receptors: a new role in cancer? , 2005, Trends in Endocrinology & Metabolism.

[20]  H. Kajiyama,et al.  Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal Dissemination , 2005, Clinical Cancer Research.

[21]  H. Ando,et al.  Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. , 2003, Human reproduction.

[22]  G. Nguyen,et al.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.

[23]  H. Ando,et al.  Premenstrual disappearance of aminopeptidase A in endometrial stromal cells around endometrial spiral arteries/arterioles during the decidual change. , 2002, The Journal of clinical endocrinology and metabolism.

[24]  D G Altman,et al.  A prognostic model for ovarian cancer , 2001, British Journal of Cancer.

[25]  R. A. Santos,et al.  Opposing actions of angiotensins on angiogenesis. , 1999, Life sciences.

[26]  M. Serio,et al.  Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. , 1999, Journal of the American Society of Nephrology : JASN.

[27]  L. Murray,et al.  Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? , 1998, The Lancet.

[28]  K. Pfeiffer,et al.  Identification and Characterization of a Novel 9.2-kDa Membrane Sector-associated Protein of Vacuolar Proton-ATPase from Chromaffin Granules* , 1998, The Journal of Biological Chemistry.